Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Finding Retinal Biomarkers in Alzheimer's Disease
Authors not listed
Assistance Publique - Hôpitaux de Paris · 2021
Abstract
CSF Alzheimer's disease (AD) biomarkers are the only one that reflect both Aβ and tau pathologies. There is increasing evidence for the presence of AD abnormalities in the retina of AD patients. Recent studies showed that they can be detected in living patients. Thus, retinal AD-linked abnormalities might be used as alternative diagnostic biomarkers for AD.
FIREBALZ study aims at identifying and validating retinal biomarkers for the diagnosis of Alzheimer's disease.
The study will include 160 patients in whom LP is indicated for assessment of CSF AD biomarkers according to French health authority (HAS) recommendations. Those patients will undergo a detailed neuro-ophtalmologic evaluation including retinal layers thickness evaluation (optical coherence tomography).
Univariate and multivariate analyses will be performed to test diagnostic properties of retinal parameters as compared to current diagnostic criteria including CSF biomarkers and logistic regression models will be used.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-01 MST
Cite this
APA
Anonymous. (2021). Finding Retinal Biomarkers in Alzheimer's Disease. <em>Assistance Publique - Hôpitaux de Paris</em>. https://clinicaltrials.gov/study/NCT05067010
Vancouver
Anonymous. Finding Retinal Biomarkers in Alzheimer's Disease. Assistance Publique - Hôpitaux de Paris. 2021.
BibTeX
@misc{anon2021Findin,
title = {Finding Retinal Biomarkers in Alzheimer's Disease},
author = {Anonymous},
journal = {Assistance Publique - Hôpitaux de Paris},
year = {2021},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Wake Forest University Health Sciences 2018
Open access · US-GOV
Identifying Novel Aging Targets for Treatment of Delirium
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau 2025
Open access · US-GOV
A Phase III, Randomized, Double-blinded Study of the Efficacy and Safety of LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (the LESS-AD Trial).
Galaxia Empírica 2023
Open access · US-GOV
Safety Evaluation of Edoxaban in Elderly Patients With Frailty Criteria
University of Bern 2018
Open access · US-GOV
Effects of Transcranial Electric Stimulation on Associative Memory Formation in Healthy Elderly Participants as Well as in Individuals With Memory Impairment
2022
Open access · CC-BY
Editor's evaluation: Biological brain age prediction using machine learning on structural neuroimaging data: Multi-cohort validation against biomarkers of Alzheimer’s disease and neurodegeneration stratified by sex
Alzheimer s Research & Therapy 2023
Open access · CC-BY